Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Frontiers in Antibiotics is Scopus-indexed (Q2, CiteScore 5), WoS ESCI, DOAJ. Published by Frontiers Media SA.
Checked against the index lists dated .
ISSN 2813-2467Verify ISSN ↗
Publisher: Frontiers Media SA
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Infectious Diseases | 124 / 361 | 65th | Q2 |
| Microbiology (medical) | 61 / 147 | 58th | Q2 |
| Pharmacology | 143 / 328 | 56th | Q2 |
| Drug Discovery | 73 / 161 | 54th | Q2 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2022–present, best quartile Q2, CiteScore 5.
Frontiers in Antibiotics is Q2 in Infectious Diseases (rank 124 of 361), Q2 in Microbiology (medical) (rank 61 of 147) and Q2 in Pharmacology (rank 143 of 328), by CiteScore 2025. It is ranked in 4 subject areas in all.
Frontiers in Antibiotics is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 5, which places it in quartile Q2 at the 65th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.854, quartile Q2, with an H-index of 11.
The publisher lists an article processing charge of about US$2,353 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Frontiers in Antibiotics is published by Frontiers Media SA. Its ISSN is 2813-2467.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
Frontiers in Antibiotics has an h-index of 15 and a 2-year mean of 3.32 citations per paper (OpenAlex). Its Scopus CiteScore is 5, quartile Q2. On 2-year citations it ranks #90 of 354 Scopus journals in Infectious Diseases.
Frontiers in Antibiotics published 23 papers in 2025; its busiest recent year was 2024 with 30. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 97 research articles (2023–2026), authors are most often from India (15.3%), United States (14.6%) and United Kingdom (8.4%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.